These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 5462094)

  • 1. [Experience with administration of mitomycin C in a massive dosage together with reduced glutathione (tathion)].
    Tsuboi S; Kajiwara T; Inoue H; Abe Y; Kamata T
    Gan No Rinsho; 1970 Feb; 16(2):129-35. PubMed ID: 5462094
    [No Abstract]   [Full Text] [Related]  

  • 2. [Studies on the administration methods of antitumor agents. (3). Massive shock administration of mitomycin C].
    Tsuboi S; Kajiwara T; Inoue H; Abe T; Kamata F
    Gan No Rinsho; 1967 Mar; 13(3):166-75. PubMed ID: 6070072
    [No Abstract]   [Full Text] [Related]  

  • 3. [Studies on the effect of bone marrow transplantation in relation to fluctuations of oxygen consumption of the bone marrow. II. Effect of bone marrow transplantation on bone marrow disorders induced by Mitomycin C in terms of tissue respiration].
    Yasuda H
    Kumamoto Igakkai Zasshi; 1967 Aug; 41(8):773-96. PubMed ID: 4867378
    [No Abstract]   [Full Text] [Related]  

  • 4. Phase I study of high-dose mitomycin with autologous bone marrow support.
    Sarna GP; Champlin R; Wells J; Gale RP
    Cancer Treat Rep; 1982 Feb; 66(2):277-82. PubMed ID: 7034933
    [No Abstract]   [Full Text] [Related]  

  • 5. [Experimental studies on the effects of shielding the spleen and bone marrow in massive dosage of mitomycin C].
    Ikejiri K
    Igaku Kenkyu; 1967 Oct; 37(5):471-89. PubMed ID: 5627805
    [No Abstract]   [Full Text] [Related]  

  • 6. [Effect of Tathion on excretion of 203Hg-MHP, (1-acetomercuri-2-hydroxypropane) from the kidney--reduction of radiation dosage to the kidney].
    Oshiumi Y; Matsuura K
    Rinsho Hoshasen; 1969 Aug; 14(8):663-8. PubMed ID: 5196163
    [No Abstract]   [Full Text] [Related]  

  • 7. Therapeutic efficacy of aortic administration of N-acetylcysteine as a chemoprotectant against bone marrow toxicity after intracarotid administration of alkylators, with or without glutathione depletion in a rat model.
    Neuwelt EA; Pagel MA; Hasler BP; Deloughery TG; Muldoon LL
    Cancer Res; 2001 Nov; 61(21):7868-74. PubMed ID: 11691805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myelotoxicity of methotrexate, mitozantrone, and mitomycin C.
    Morton AR; Anderson H; Howell A
    Lancet; 1987 Jun; 1(8548):1494. PubMed ID: 2885486
    [No Abstract]   [Full Text] [Related]  

  • 9. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity.
    Rosenblum MG; Verschraegen CF; Murray JL; Kudelka AP; Gano J; Cheung L; Kavanagh JJ
    Clin Cancer Res; 1999 May; 5(5):953-61. PubMed ID: 10353726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Chemotherapy of stomach cancer-with special reference to massive and intermittent administration of mitomycin C].
    Matsunaga F; Shimoyama T; Mikawa K; Ishiwata J; Kikuchi H
    Naika; 1966 Jun; 17(6):1101-15. PubMed ID: 5964528
    [No Abstract]   [Full Text] [Related]  

  • 11. [Effect of deoxydized glutathione (Tathion) on excretion of 203Hg-MHP in kidney].
    Oshiumi Y; Matsuura K; Komaki S
    Nihon Igaku Hoshasen Gakkai Zasshi; 1969 Nov; 29(8):1038-46. PubMed ID: 5263738
    [No Abstract]   [Full Text] [Related]  

  • 12. Phase I-II study of mitomycin C topical therapy for low-grade, low stage transitional cell carcinoma of the bladder: an interim report.
    DeFuria MD; Bracken RB; Johnson DE; Soloway MS; Merrin CE; Morgan LR; Miller HC; Crooke ST
    Cancer Treat Rep; 1980; 64(2-3):225-30. PubMed ID: 7407754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Case of bone marrow disorders due to carcinostatics, remarkably improved by transplantation of the homologous fetal hematopoeitic tissue].
    Shimada M
    Gan No Rinsho; 1967; 13(4):275-81. PubMed ID: 5624322
    [No Abstract]   [Full Text] [Related]  

  • 14. Myelosuppression after methotrexate, mitozantrone, and mitomycin C combination chemotherapy.
    Powles TI; Ashley S
    Lancet; 1987 Oct; 2(8563):853. PubMed ID: 2889049
    [No Abstract]   [Full Text] [Related]  

  • 15. [Protective effects of juzen-taiho-to on the adverse effects of mitomycin C].
    Iijima OT; Fujii Y; Kobayashi Y; Kuboniwa H; Murakami C; Sudo K; Aburada M; Hosoya E; Yamashita M
    Nihon Gan Chiryo Gakkai Shi; 1988 Jun; 23(6):1277-82. PubMed ID: 3148020
    [No Abstract]   [Full Text] [Related]  

  • 16. [Basic studies on diagnosis of bone marrow diseases using NMR].
    Muranaka A; Otsuka N; Saito J; Yanagimoto S; Tomomitsu T; Ito Y; Morita R
    Kaku Igaku; 1983 Nov; 20(9):1349-54. PubMed ID: 6427496
    [No Abstract]   [Full Text] [Related]  

  • 17. [Introduction of new therapeutic method in uterine cancer. Hiraoka's extraperitoneal blockage of pelvic circulation combined with administration of mitomycin].
    Hiraoka O
    Sanfujinka No Jissai; 1970 Oct; 19(10):1021-37. PubMed ID: 5536199
    [No Abstract]   [Full Text] [Related]  

  • 18. Mitomycin C: phase I study of a constant infusion ambulatory treatment schedule.
    Lokich J; Perri J; Fine N; Bothe A; Nelson T; Greene R; Zipoli T
    Am J Clin Oncol; 1982 Aug; 5(4):443-7. PubMed ID: 7113965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pre-operative chemotherapy of stomach cancer combined with local administration of OK-432--evaluation of macroscopic results].
    Mukai M; Den N; Yamazaki Y; Namiki S; Oda S; Nagao K
    Gan To Kagaku Ryoho; 1982 Jan; 9(1):96-102. PubMed ID: 6820880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Delayed adverse skin reactions associated with mitomycin-C administration.
    Wood HA; Ellerhorst-Ryan JM
    Oncol Nurs Forum; 1984; 11(4):14-8. PubMed ID: 6236431
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.